Every Form 4 that AN2 Therapeutics, Inc. (ANTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANTX filings page.
AN2 Therapeutics officer reports small stock sales tied to RSU taxes. Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 17,923 shares of AN2 Therapeutics common stock on January 5, 2026 at a weighted average price of $1.0014 per share, followed by 6,931 shares on January 6, 2026 at $1.012 per share. According to the footnotes, these shares were sold pursuant to the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on January 1, 2026. After the reported transactions, Eizen directly beneficially owned 152,499 shares of common stock, which include multiple RSU awards that vest over several years, subject to his continued service.
AN2 Therapeutics (ANTX) insider activity: Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 2,819 shares of common stock at $1.14 on November 4, 2025, to satisfy tax withholding from RSU vesting. Following the transaction, he beneficially owns 177,353 shares.
The holdings figure includes RSU grants: 31,500 RSUs vesting annually in quarters from November 4, 2024; 22,500 RSUs vesting annually in thirds from January 1, 2025; and 45,000 RSUs with two-thirds vesting on January 1, 2026 and one-third on July 1, 2026, subject to continuous service. The total also reflects the purchase of 5,000 shares under the 2022 ESPP on September 30, 2025.
AN2 Therapeutics (ANTX) reported an insider transaction by Chief Strategy Officer Stephen David Prior. On 11/04/2025, he sold 765 shares of common stock at $1.14 per share, a sale made to satisfy tax withholding from the vesting of RSUs. Following this transaction, he beneficially owned 65,548 shares.
His equity includes 10,125 RSUs that vest 1/4 annually over four years from November 4, 2024, and 12,031 RSUs that vest on January 1, 2026, each contingent on continued service. The holdings also reflect the purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on September 30, 2025.